Have you ever heard of Secretariat? Secretaria

Have you ever heard of Secretariat?

Secretariat was the greatest race horse to ever live, winning the last leg of the triple crown by 31 lengths. Unheard of. Unbelievable. Simply Amazing.

Everything we have been feeling and thinking about Leronlimab.

So now think about Leronlimab as Covid's Secretariat. A drug that's so much better than the standard of care that CD12 results should be a 31 length runaway win.

But it wasn't. Leronlimab finished outside of the money, a distant fourth.

Then some astute fellow wearing a derby hat and holding a rolled up copy of the daily racing form in his hands spits out what's left of his unfiltered cigarette and calmly asks to see a replay. Where it becomes clear that Leronlimab was held in the gate until well after the rest of the horses hit the half mile pole.

Well, that isn't fair.

How's a horse supposed to win if he doesn't get to start at the same time as the others? In fact he can't win. But wouldn't you know Leronlimab somehow made almost all of that half mile handicap up before it was over. His 1/4 and 1/2 mile fractions were way better than any other horse in the race. But he was only able to get up to fourth place before it was over and everyone who bet on Leronlimab lost.

It was a failure of a race.

The results of CD12 are not fishy. It's clear as day what happened. It was a rigged race. Leronlimab was randomly saddled with way more patients that were 3.5x more likely to die than the patients in the placebo arm. The placebo arm had a half mile lead in the race and even with that Leronlimab was able to show some significance and powerful stats that on any other day would likely result in a 31 length lead. Adding 140 more patients removes the half mile lead the placebo group had and will allow Leronlimab results to show exactly how many lengths ahead of the standard of care it really is.

Hopefully that helps you understand that nothing was rigged and nothing is fishy. Cytodyn got extremely unlucky with the randomization of patients and it was simply too much to overcome. The good news is that despite that terrible luck Leronlimab still showed some tremendous efficacy. We just need to rerun the first half the race without the gate malfunctioning.